Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation

Similar documents
Kidney Cancer OVERVIEW

A912: Kidney, Renal cell carcinoma

Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma

Stage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center

Significant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell Carcinoma at a Private and Public Hospital in Brazil

Incidental Detection of Renal Cell Carcinoma is an Independent Prognostic Marker: Results of a Long-Term, Whole Population Study

BACKGROUND. Evidence exists to suggest a pattern of increasing early diagnosis

Renal cell cancer: pathologic and prognostic factors and new staging strategies

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

Louisiana Cancer Facts & Figures Kidney Cancer 2016

The WHO Classification of Renal Tumors and Common Issues in TNM Staging for Renal Cell Carcinoma

RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE

The TV Series. INFORMATION TELEVISION NETWORK

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Medullary Renal Cell Carcinoma Case Report

RCC accounts for 3% of all malignant tumors and now

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

Renal cell carcinoma and body composition:

RENAL CELL CARCINOMA EPIDEMIOLOGY

Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer

Survival analysis of 220 patients with completely resected stage II non small cell lung cancer

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Renal Tumors in Young Adults A Single-Center Experience From a Developing Country

Kidney Cancer (Adult) - Renal Cell Carcinoma What is cancer?

INTRODUCTION: CASE REPORT:

New Hampshire Childhood Cancer

Thyroid and Adrenal Gland

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

CT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma. Melissa Price, MD Aoife Kilcoyne, MD Mukesh G.

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Report series: General cancer information

EUROPEAN UROLOGY 60 (2011)

Kidney Cancer (Adult) - Renal Cell Carcinoma What is cancer?

CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal

Renal Cell Carcinoma. Background 1. General information. Pathophysiology 1. Pathology of disease. Diagnostics 1. History

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科

Kidney Cancer: Survival Report. Urological Cancers SSCRG

Advances and controversies in grading and staging of renal cell carcinoma

Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics

Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

Early mortality rate (EMR) in Acute Myeloid Leukemia (AML)

Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation

Four Important Facts about Kidney Cancer

Survival among Black and White Patients with Renal Cell Carcinoma in an Equal-Access Health Care System. Kangmin Zhu 1,4*

Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of Renal Tubular Origin

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Translocation Renal Cell Carcinomas

The Ontario Cancer Registry moves to the 21 st Century

Guidelines for Management of Renal Cancer

Surgical Management of Kidney Cancer. Adam R. Metwalli, M.D. Urologic Oncology Branch National Cancer Institute

La sopravvivenza dei tumori maligni nei confronti internazionali: anticipazione della diagnosi o modifica del decorso naturale della malattia?

KIDNEY CANCER (ADULT) - RENAL CELL CARCINOMA

Update on Mesothelioma

Cancer in Ireland 2013: Annual report of the National Cancer Registry

Something Old, Something New.

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA

LIVER CANCER AND TUMOURS

Chapter 14 Cancer of the Cervix Uteri

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules

THYROID CANCER. I. Introduction

Image SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.

Corso di Oncologia Medica, AA RENAL CELL CARCINOMA

Rare Thoracic Tumours

The effect of the introduction of ICD-10 on cancer mortality trends in England and Wales

Epidemiology and Staging of Renal Cell Carcinoma

analyses relied on T stage, Fuhrman grade and presence of enm. Data were analysed using univariable, multivariable and stratified analyses.

Frozen Section Diagnosis

GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.

OBJECTIVES By the end of this segment, the community participant will be able to:

Metastatic renal cell carcinoma to the left maxillary sinus

Renal Pathology Update. Sundus Hussein MD, FRCPC

SRO Tutorial: Prostate Cancer Treatment Options

Histologic Subtypes of Renal Cell Carcinoma

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?

General Rules SEER Summary Stage Objectives. What is Staging? 5/8/2014

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

Metastatic Prostate Cancer Causing Complete Obstruction of the IVC

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD

Pattern of metastases in renal cell carcinoma: a single institution study

Role of histopatological assessment of renal cancer specimen after radical and partial nephrectomy

GUIDELINES ON RENAL CELL CARCINOMA

Critical Illness Products in South Africa

Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies

Skin Cancer: The Facts. Slide content provided by Loraine Marrett, Senior Epidemiologist, Division of Preventive Oncology, Cancer Care Ontario.

A new score predicting the survival of patients with spinal cord compression from myeloma

Lung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?

Number. Source: Vital Records, M CDPH

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities

Genetics Gender plays a role in kidney cancer, as men are twice as likely as women to develop RCC

4/8/13. Pre-test Audience Response. Prostate Cancer Screening and Treatment of Prostate Cancer: The 2013 Perspective

PARANEOPLASTIC SIGNS AND SYMPTOMS OF RENAL CELL CARCINOMA: IMPLICATIONS FOR PROGNOSIS

Transcription:

Indian J Med Res 140, November 2014, pp 624-629 Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation Shalini Agnihotri, Jatinder Kumar, Manoj Jain *, Rakesh Kapoor & Anil Mandhani Departments of Urology & * Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India Received September 26, 2012 Background & objectives: Clinical spectrum of most of the diseases in developing countries is different from the west. Similarly whether renal cell carcinomas (RCC) in a developing country like India is seen in the same spectrum in relation to the age at presentation as in the west is not described in the literature. This study was carried out to investigate the spectrum of RCC in India with regards to age of onset, stage at presentation and survival. Methods: Patients with renal tumour, treated between January 2000 to December 2012 in a tertiary care hospital in north India, were analyzed for age at presentation, clinical features and histopathological characteristics. Clinical diagnosis was made by contrast enhanced computerized tomography (CECT) scans and/or magnetic resonance imaging (MRI). Renal masses diagnosed as angiomyolipoma, infective masses and hydatid cysts were excluded from the analysis. Impact of various age groups on gender, tumour size, TNM stage, Fuhrman grade, histopathological subtypes, lymph node, inferior vena cava (IVC) involvement and survival was analyzed. Patients were grouped in five age groups i.e. 39, 40-49, 50-59, 60-69 and more than 70 yr of age. Results: Of the total 617 patients with 617 renal tumours (2 patients had bilateral tumours but only the larger tumour was considered) clinically suspected as RCC, 586 had epithelial cell tumour and the remaining 31 had non epithelial cell tumour. The mean tumour size was 8.08±3.5 cm (median 7, range 1-25 cm). Tumour of less than 4 cm size was present in only 10.4 per cent patients. The mean age at diagnosis was 55.15±13.34 (median 56, range 14-91 yr) years. A total of 30.03 per cent of renal tumours presented in patients younger than 50 yr of age. Though there was no difference in stage, Fuhrman s grade, IVC involvement and lymph nodal spread among various age groups, younger patients had higher proportion of non clear cell RCC and only 48.59 per cent of them presented with conventional RCC. Mean survival was lower in patients younger than 39 yr with HR of 1.7 (0.8-3.2). Interpretation & conclusion: Our results showed that renal cell carcinoma was more frequent in younger people in India. One third of the patients were less than 50 yr of age and only 10.4 per cent patients had tumour of less than 4 cm (T1a). Younger patients of <39 yr of age had relatively lower survival rates. Key words age at presentation - clear cell - renal cell carcinoma - survival - tumour 624

Agnihotri et al: RCC with relation to age of onset & presentation 625 Renal cell carcinoma (RCC) accounts for 3 per cent of all adult cancer and 85 per cent of all kidney tumours 1. RCC is primarily a disease of elderly and typically presents in the sixth and seventh decades of life 2,3. Incidence rates are race dependent and have been reported as 10 to 20 per cent higher in African Americans for unknown reasons 3. Data from Indian population on age at presentation and its relation with various histopathological characteristics are lacking. Clinical spectrum of most of the diseases in developing countries is different from the west. This study was aimed at analyzing the clinico-pathological characteristics of RCC and survival of patients in relation to the age at presentation in India. Material & Methods From January 2000 to December 2012, patients with renal masses treated at the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, were analyzed. Data were collected from the hospital information system (HIS) and oncology data registry cell in the department of urology. All the patients had either contrast enhanced computerized tomography (CECT) scans and/or magnetic resonance imaging (MRI) to characterize the renal tumour. Renal masses diagnosed as angiomyolipoma, infective masses and hydatid cysts were excluded from the analysis. To see the association of the disease at presentation and its clinical and pathological characteristics with age, patients were divided into five age groups as 39, 40-49, 50-59, 60-69 and more than 70 years. Variables studied were gender, tumour size, TNM stage, Fuhrman grade, histopathological subtypes, lymph node involvement and inferior vena cava (IVC) thrombus. Pathological tumour staging and grading were done according to an updated staging system by the American Joint Committee on Cancer (AJCC) and the Union Internationale Contre le Cancer (UICC) 4,5. T1 was considered as tumours of <7 cm of size, T2 of > 7cm, T3 included tumours involving perinephric fat, renal vein or IVC thrombus, T4 included Gerota s fascia involvement or contiguous involvement of the adrenal gland and metastatic RCC included non contiguous adrenal metastasis, extra regional lymph node or soft tissue disease. Owing to the shift in treatment of RCC towards partial nephrectomy for tumours of < 4 cm, T1 tumours were further classified as T1a for tumours of <4 cm and T1b for tumours of 4-7 cm size. Histological subtypes were divided as per the classification of world health organization 6. All the age groups were compared for clinical and histopathological features. Frequencies and proportions were evaluated for categorical variables by chi-square test. A Cox proportional hazard analysis was also performed, including relative risk and confidence intervals (CI). Finally, the Cox proportional risk regression model was fitted to data to estimate the independent prognostic importance of survival. Twenty four patients, who were lost to follow up, were excluded from the analysis. Also 11 patients who died in immediate post-operative period (8) and due to other causes (5) in follow up were excluded from the analysis. Cancer specific survival (CSS) analysis was done only in 551 patients. The end point of interest was survival time, defined as the time from treatment initiation to the death or the last follow up date. The relationship between CSS and each of the variables was analyzed using the log-rank test for categorical variables. Survival analysis was done by using Kaplan- Meier curve. All P values were two-sided, and P<0.05 was considered significant. The analysis was done using the Statistical Package for the Social Sciences version 17 (SPSS Inc, Chicago, IL, USA). Results Of the total 617 patients with 617 renal tumours (2 patients had bilateral tumours but only the larger tumour was considered) which were clinically suspected as RCC, 586 had epithelial cell tumour. the remaining 31 patients had non epithelial cell tumour. Patients and tumour characteristics are described in tables I and II. The mean size of the tumours was 8.08 ± 3.5 cm (median 7, range 1-25 cm). The mean age at diagnosis was 55.15±13.34 (median 56, range 14-91) years. The percentage distribution of renal tumours in various age Table I. Age distribution and frequency of renal tumour at presentation (N=617) Age category (yr) Frequency of renal tumours N (%) 39 76 (12.3) 40-49 114 (18.5) 50-59 178 (28.8) 60-69 154 (25.0) >70 95 (15.4) Total 617 (100)

626 INDIAN J MED RES, november 2014 Table II. Histopathological findings of clinically diagnosed renal tumour (N=617) Epithelial malignancy (N= 586) Total number (%) Clear cell 418 (67.7) Papillary 61 (9.8) Chromophobe 29 (4.7) Collecting duct 4 (0.6) Oncocytoma 12 (1.9) Metastatic or non-operated 29 (4.7) PNET 9 (1.4) Tubulocystic 1 (0.2) Metanephric adenoma 2 (0.3) Sarcomatoid 20 (3.2) Others 1 (0.2) Non epithelial malignancy (N=31) XGP 4 (0.6) TCC 8 (1.3) Pheochromocytoma 1 (0.2) Sarcoma 15 (2.4) Metastasis from thyroid 1 (0.2) Ganglioneuroma 1 (0.2) Lymphoma 1 (0.2) PNET, primitive neuro ectodermal tumor; TCC, transitional cell carcinoma; XGP, xanthogranulamatous groups was 12.3, 18.5, 28.8, 25.0 and 15.4 per cent, respectively. A total of 190 (30.03%) patients presented at age younger than 50 yr with renal tumours (Table I). The disease was organ confined (pt1 and pt2) in 346 (59%) of the patients and among those, pt1a (tumour <4 cm) was present in only 61/346 (17.6%), but clinically the percentage of T1a 61/586 (10.4%) was low (Table IV). Male preponderance was seen in patients of all age groups. There was no difference in clinical stage of the tumour, tumour size, tumour grade, presence of lymph nodes and IVC thrombus in different age groups. The relationship between age categories and histopathological subtypes are described in table III. Apart from the sex ratio, histological subtypes were significantly different among the age categories. Overall, the proportion of patients presenting with clear cell carcinoma was 71.33 per cent. This proportion was even less (48.59%) in patients younger than 50 yr of age. Mean follow up was 27.8±21.2 (range 6-121) months. Though age per se did not affect the survival, the mean value of cancer specific survival in younger patients of <39 yr was lower than the older patients of >70 yr, Hazard ratio (HR) of 1.7 (0.8-3.2). (Table V, Figure) Five year cancer specific survival rates in patients of 39, 40-49, 50-59, 60-69 and more than 70 yr of age were 53.3, 75, 60, 65 and 80 per cent, respectively. Discussion Renal cell carcinoma, based on the data from developed countries, is considered to be the malignancy of 6 th and 7 th decade of life but there are no data available from the developing country to support this. It has been observed that in India, more and more patients are presenting at a younger age and in advanced stage of the disease. In contrast to the western countries where more than 60 per cent of the RCC has been reported to present as less than 4 cm size (T1a), only 10.4 per cent of our patients were picked up as T1a, which is an ideal size for partial nephrectomy 7. One third of the total patients with RCC were younger than 50 yr of age at the time of presentation. Data from the larger epidemiological studies from west have shown that around 3.4 to 5 per cent of patients with the renal tumour were of less than 40 yr of age 8, while in our study 12.3 per cent of patients were below the age of 40 yr. In a study from Surveillance Epidemiology and End Results (SEER) database, majority of RCC cases at presentation were between 60-69 or 70-79 yr of age and only 42 per cent of patients presented in < 60 yr of age 9. in the present study, 60.2 per cent of patients were below the age of 60 yr. Unlike in west where the male to female ratio is 2:1, males were 4-times likely to present with renal tumours in our population 10-12. Proportion of female patients was more in younger age group, while in a study from west, proportion of female patients increased towards older age, where about 44.7 per cent of patients were females 10. This difference in sex ratio may reflect the difference in perception in seeking health care for a male and a female member of the family looking at the limited financial resources in a developing country like India. Another difference observed was the incidence of clear cell RCC. Contrary to most of the western literature 9,12-14 where clear cell RCC is present in

Agnihotri et al: RCC with relation to age of onset & presentation 627 Table III. Relationship between age categories and histopathological subtypes of renal cell carcinoma (RCC) Variables Age categories (yr) N =586 Sex Male Female Histology 39 (N=71) 44 (61.9) 27 (38.0) 40-49 (N=105) 77 (73.3) 28 (26.6) 50-59 (N=175) 139 (79.4) 36 (20.5) 60-69 (N=145) 120 (82.7) 25 (17.2) >70 (N=90) 81 (90.0) 9 (10.0) Total (N=586) 461 (78.6) 125 (21.4) Clear cell 36 (50.7) 68 (64.8) 132 (75.4) 111 (76.6) 71 (78.9) 418 (71.33) Papillary 9 (12.7) 11 (10.5) 18 (10) 17 (11.7) 6 (6.7) 61 (10.4) Chromophobe 5 (7.0) 14 (13.3) 4 (2.3) 2 (1.4) 4 (4.4) 29 (4.94) Collecting duct 3 (4.2) 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 4 (0.68) Oncocytoma 2 (2.8) 2 (1.9) 5 (2.9) 1 (0.7) 2 (2.2) 12 (2.05) Other 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) Sarcomatoid 1 (1.4) 5 (4.8) 5 (2.9) 6 (4.1) 3 (3.3) 20 (3.41) Mets or non Operated 6 (8.5) 5 (4.8) 8 (4.6) 6 (4.1) 4 (4.4) 29 (4.95) PNET 5 (7.0) 0 (0.0) 3 (1.7) 1 (0.7) 0 (0.0) 9 (1.5) Tubulocystic 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) Metanephric 2 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.34) Values in parentheses are percentages PNET, primitive neuro ectodermal tumor Table IV. Distribution of stage of RCC at presentation (N= 586) Stage of renal tumour Total number (%) T stage (n=586) T1 200 (34.1) T2 146 (24.9) T3 107 (18.3) T4 & lymph node 93 (15.9) Metastatic in-operable 27 (4.6) Metastatic operable 13 (2.2) Tumours of <4 cm T1a Clinical T1a Pathological T1a among T1 and T2 61/586 (10.4) 61/346 (17.6) around 85 per cent of the patients, clear cell RCC in the current study was present only in 71.33 per cent of the patients 9,12-14. Clear cell RCC was uniformly higher in all age groups ranging from 82 to 88 per cent in (SEER) data 9 but in the present study younger patients had less proportion of clear cell carcinoma ranging from 50.7-64.8 per cent. Our study demonstrated a lower survival rate in younger patients and also highlighted the fact that more patients presented at younger age in comparison to patients from the west. Though the known risk factors for RCC such as smoking, hypertension, obesity, and diet have not been studied in different geographical area, this data set may provide a basis to find out the reasons for this difference in presentation at the younger age and poor survival 15,16. As RCC is an immunogenic malignancy where body immunity plays an important role, the plausible hypothesis we put forth for younger age at presentation is the comparatively poorer nutritional status of younger population in developing countries, which could be analogous to the nutritional status of elderly people in a developed country. This needs to be validated prospectively by

628 INDIAN J MED RES, november 2014 Age group (yr) Table V. Mean survival of patients with renal cell malignancy with hazard ratio (N=551) Mean survival (%) Number 5-year survival (%) Event >70 92.4 81 80 16 Log Rank p value HR (95% CI) Reference 60-69 73.5 136 65.5 21 0.8 (0.4-1.6) 0.6 50-59 66.8 165 60.0 26 0.14 1.0 (0.5-1.9) 0.9 40-49 62.9 101 75.0 14 0.8 (0.4-1.7) 0.6 < 39 59.7 68 53.3 21 1.7 (0.8-3.2) 0.1 HR, hazard ratio P value Duration in months Fig. Kaplan Meier s survival curve depicting the survival of patients of renal cell malignancy based on different age groups. assessing nutritional status by standardized instruments to measure nutritional status. Though we did not observe variation in the incidence of localized versus metastatic RCC at the time of presentation, the average size of the tumour at presentation was 8.08 cm. This could be explained by a higher proportion of men presenting with symptom. we have earlier reported that only 28 per cent of RCC were detected incidentally on imaging i.e. ultrasonography or CECT done for other causes like nonspecific abdominal symptoms, lower urinary tract symptoms, pyrexia of unknown origin, etc 17. Another finding was that only 10.4 per cent of our patients presented with the tumour size of less than 4 cm, whereas in the west, almost two third of the kidney tumours were small in size 7. Apart from the difference in proportion of clear cell RCC and sex ratio in various age groups, no difference was found in Fuhrman s grade, stage of the tumour, lymph node metastases, involvement of IVC and distant metastasis, which are the important prognosticating factors for the treatment outcome.

Agnihotri et al: RCC with relation to age of onset & presentation 629 In conclusion, one third of our patients with RCC presented at less than 50 yr of age with relatively higher mean tumour size of 8.08 cm. Though there was no difference in Fuhrman s grade, stage of the tumour, lymph node metastases, involvement of IVC and the distant metastasis in various age groups, the proportion of clear cell RCC was relatively small in younger age group patients. the survival was much lower in younger age group. The reason for difference in presentation at the younger age from the western population is worth exploring. References 1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J 2010; 60 : 277-300. 2. 3. 4. 5. Pantuck AJ, Zisman A, Beldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166 : 1611-23. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281 : 1628-31. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7 th edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol 2010; 17 : 1471-4. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphological parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6 : 655-63. 6. lopez-beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004. WHO classification of renal tumors of the adults. Eur Urol 2006; 49 : 798-805. 7. Salagierski M, Akdogan B, Brookman-May S, Dobrowdska- Glazar B, Ficarra V, Langenhuijsen JF, et al. What is the contemporary role of radiofrequency ablation in the management of small renal masses? Are small lesions the radiologist s tumors? Eur Urol 2013; 63 : 493-5. 8. Kantor AL, Meigs JW, Heston JF, Flannery JT. Epidemiology of renal cell carcinoma in Connecticut, 1935-1973. J Natl Cancer Inst 1976; 57 : 495-500. 9. Sun M, Abdollah F, Bianchi M, Trinh Q, Jeldres C, Tian Z, et al. A stage-for-stage and grade-for grade analysis of cancer specific mortality rates in renal cell carcinoma according to age: A competing-risks regression analysis. Eur Urol 2011; 60 : 1152-9. 10. Taccoen X, Valeri A, Descostes JL, Morin V, Stindel E, Doucet L, et al. Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancerspecific survival. Eur Urol 2007; 51 : 980-7. 11. Jun C, Zhishun X, Xianzhou J, Qiang F, Jin W. Association between age and clinical characteristics of renal cell carcinoma in adult patients. Int J Urol 2006; 13 : 515-9. 12. Verhost G, Veillard D, Guille F, De La Taille A, Salomon L, Abbou CC, et al. Relationship between age at diagnosis and clinicopathological features of renal cell carcinoma. Eur Urol 2007; 51 : 1298-304. 13. Patard JJ, Tazi H, Bensalah K, Rodriguez A, Vincendeau S, Riox-Leclercq N, et al. The changing evolution of renal tumors: A single center experience over a two decade period. Eur Urol 2004; 45 : 490-3. 14. Sanchez-Ortiz RF, rosser J, Lydia T, David A, Wood G. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol 2004; 171 : 2160-5. 15. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006; 176 : 2353-8. 16. Amling CL. The association between obesity and the progression of prostate and renal cell carcinoma. Urol Oncol 2004; 22 : 478-84. 17. Jain P, Surdas R, Aga P, Jain M, Kapoor R, Srivastava A, et al. Renal cell carcinoma: Impact of mode of detection on its pathological characteristics. Indian J Urol 2009; 25 : 479-82. Reprint requests: Dr Anil Mandhani, Professor, Department of Urology & Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226 014, India e-mail: mandhanianil10@gmail.com